Di-(2-ethylhexyl) phthalate (DEHP) is widely utilized as a plasticizer in industrial manufacturing to enhance the durability and flexibility of plastics. Studies have depicted that DEHP exposure may be associated with multiple cancers, including colorectal, liver and prostate cancer. However, the effects and underlying mechanisms of DEHP on bladder cancer progression remain unspecific. In this work, we explored the correlation between DEHP exposure and bladder cancer through comprehensive analysis. A total of 172 differentially expressed DEHP-related genes (DEDRGs) were screened based on the CTD and TCGA database. In addition, a new prognostic model related to DEHP was developed, which had excellent predictive power for bladder cancer prognoses. Molecular docking techniques were employed to assess the binding affinity of mono(2-ethylhexyl) phthalate (MEHP) to crucial proteins. Lastly, both in vitro and in vivo experiments, along with RNA sequencing, were conducted to elucidate the biological roles and mechanisms of MEHP in bladder cancer. Several new insights into the role of DEHP/MEHP in bladder cancer were given in this study, as well as an awareness of the association between environmental toxicants and cancer progression.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.envpol.2024.125625 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Detection and interpretation of PD-L1 in urologic neoplasms].
Zhonghua Bing Li Xue Za Zhi
January 2025
Department of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University Health Science Center, Beijing100191, China.
Immune checkpoint inhibitors targeting PD-1/PD-L1 are gradually being applied in the treatment of advanced urinary system tumors. Immunohistochemical analysis of PD-L1 expression is the most popular method for screening suitable patients for immunotherapy and predicting therapeutic efficacy. The current application status of PD-L1 detection for urinary system tumors (mainly urothelial carcinoma), methods of the different antibody tests and the precautions, challenges and solutions in the interpretation of immunostaining were summarized in this review.
View Article and Find Full Text PDFLethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.
J Immunother Cancer
January 2025
NHC Key Laboratory of Glycoconjugate Research, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China
Background: The E3 ubiquitin ligase murine double minute 2 (MDM2) binds the p53 transcriptional activation domain and acts as a potent inhibitor of pathway, one of the three most crucial oncogenic pathways in urothelial carcinoma (UC). However, the clinical significance and impact on tumor immune contexture of amplification in UC remain unclear.
Methods: This study analyzed 240 patients with UC with matched clinical annotations from two local cohorts (ZSHS cohort and FUSCC cohort).
Lower urinary tract sub-structures as predictors of late urinary toxicity in concurrent chemo-radiotherapy for anal cancer.
Radiother Oncol
January 2025
Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
Background And Purpose: Late toxicity is substantial after chemotherapy for anal cancer. This study aimed to investigate the relationship between radiation dose to lower urinary tract sub-structures and the risk of late urinary toxicities, in patients with anal cancer treated with chemoradiotherapy or radiotherapy.
Materials And Methods: From 2015 to 2021, 314 patients with localized anal cancer were included in a national prospective registration study.
Unveiling ADAMTS12: A Key Driver of Bladder Cancer Progression via COL3A1-Mediated Activation of the FAK/PI3K/AKT Signaling Pathway.
J Biol Chem
January 2025
Department of Urology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, P.R.China. Electronic address:
Bladder cancer (BCa) is a common and lethal disease characterized by high recurrence rates and limited treatment options. Understanding the molecular pathways of BCa progress is crucial for investigating more effective targeted therapies. While ADAMTS12 is known to contribute to cancer progression and treatment resistance, its prognostic significance and underlying mechanisms in BCa remain poorly understood.
View Article and Find Full Text PDFExploration of an adaptive proton therapy strategy using CBCT with the concept of digital twins.
Phys Med Biol
January 2025
Department of Radiology Oncology, Emory University, Clifton Rd, Atlanta, Georgia, 30322-1007, UNITED STATES.
This study aims to develop a digital twin (DT) framework to achieve adaptive proton prostate stereotactic body radiation therapy (SBRT) with fast treatment plan selection and patient-specific clinical target volume (CTV) setup uncertainty. Prostate SBRT has emerged as a leading option for external beam radiotherapy due to its effectiveness and reduced treatment duration. However, interfractional anatomy variations can impact treatment outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!